Catalyst overview
Research summary
This catalyst tracks a Phase 2 update for Pemvidutide (ALT-801) (GLP-1R/GCGR) in Alcohol Use Disorder (AUD). The expected timing is based on the latest available company guidance and may change.
RECLAIM Trial. 5/19/25- Initiated Ph2 study. 11/3/25- Enrollment completed. On track to complete 24-wk treatment period & announce topline results in 2026. 11/06/25:- Enrollment completed early; FDA granted Fast Track for AUD. Topline RECLAIM Phase 2 results expected in 2026. 03/05/26:- Topline RECLAIM Ph2 AUD data now expected in Q3 2026. 05/13/26:- RECLAIM Ph2 AUD trial ongoing; topline data expected Q3 2026 from 24-week, ~100-patient placebo-controlled study. 07/28/26:- RECLAIM Ph2 topline positive; met primary/secondary endpoints. Plans to request End-of-Ph2 FDA meeting; conference submission planned. 08/12/26:- Positive RECLAIM Ph2 topline results reported. End-of-Phase 2 FDA meeting will be requested; timing is TBA.
Verification
Confirm timing and program details against the company announcement or filing.